Science of Alli Diet Pill
GlaxoSmithKline marketed the Product over the counter in the trade name of Alli. The drug is Orlistat or tetrahydeolipstatin. It is a drug is for treating obesity. The primary function of the drug is to absorb fat from the food intake of a human body and thereby reduce the calorific value of the food taken. But, the food also should be proportioned and as specified the physician. Tetrahydeolipstatin or Orlistat is basically lipstatin’s saturated derivative version. Lipstatin is a natural inhibitor of lipases found in pancreas in human body and lipases is a product isolated from streptomyces toxytricini, bacteria. But, for stability and ease by which the product can be manufactured Orlistat is chosen instead of Lipstatin.
Orlistat inhibits lipase of the pancreas. Lipase being an enzyme breaks down Triglycerides in the intestine. Triglycerides in the diet could never have been hydrolyzed into absorbable free fatty acids without the enzyme lipase and would have been thrown out as undigested excreta. A trace of orlistat is absorbed in a systematic manner and the effect is lipase inhibition in the gastro intestinal tract after a normal dose. The route of elimination is through the feces. It is claimed that orlistat can achieve the target of nearly 30% fat elimination from the diet and preventing the same from absorption the body by taking the prescribed dose of 120 mg. Taken three times a day before meals.
However, the efficacy of orlistat varies. Clinical tests carried out revealed from 35.5% to 54.8% subjects achieved 5% or more of weight reduction in the body and to note that all these reduction is not restricted to fat portion of the body. But, between 16.4% to 24.8% achieved a reduction of 10% body mass. Significantly, after orlistat was stopped, a good number of cases regained weight up to 35% of what was lost. But, irrespective of weight loss, there was a reduction of 37% in the incidence of Type 2 diabetes.